Global Non-alcoholic Steatohepatitis (NASH) Biomarker Market

1
The Global NASH Biomarker Market to Surge at CAGR
of 21.28 by 2028
Triton Market Research presents the Global
Non-Alcoholic Steatohepatitis (NASH) Biomarker
Market segmented by Industry Verticals (Hospital,
Academic Research Key, Pharma CRO Industry,
Diagnostic Lab), Type (Oxidative stress
Biomarker, Apoptosis Biomarker, Hepatic fibrosis
Biomarker, Serum Biomarker, Other Types), and by
Geography (Asia-Pacific, North America, Middle
East and Africa, Latin America, Europe). It
further discusses the Market Summary, Industry
Outlook, Key Insights, Impact of COVID-19,
Porter's Five Forces Analysis, Market
Attractiveness Index, Vendor Scorecard, Key
Market Strategies, Drivers, Restraints,
Opportunities, Competitive Landscape, Research
Methodology Scope, Global Market Size,
Forecasts Analysis (2021-2028).
GLOBAL NASH BIOMARKER MARKET 2021-2028
CAGR 21.28 The regional paradigm of NASH
BIOMARKER Market was dominated by North America
by capturing a majority of revenue share. On the
other hand. Asia Pacific is anticipated to be the
fastest growing regional market over the forecast
period. www.tritonmarketresearch.com
Request a Free Sample https//www.tritonmarketres
earch.com/reports/non-alcoholic-steatohepatitis-bi
omarker-market Triton's report estimates the
global non-alcoholic steatohepatitis (NASH)
biomarker market to advance in revenue at a CAGR
of 21.28 during the phase of 2021-2028. NASH
refers to a more severe form of non-alcoholic
fatty liver disease, which can develop into
disorders like cirrhosis and hepatocellular
carcinoma. A NASH biomarker is used in several
verticals, including hospitals, diagnostic labs,
and pharma, among others. Factors such as growth
opportunities in the developing regions and the
surge in awareness pertaining to non-alcoholic
fatty liver disease generate new opportunities
for the NASH biomarker market. The emerging
regions are offering several opportunities to
NASH therapeutics manufacturers due to the
improvement in healthcare infrastructure, rise in
prevalence of NASH, and surge in demand for
2
healthcare services. Along with this, the growing
geriatric population in these nations is also
likely to surge the need for NASH therapeutics,
driving the studied market's growth. However, the
side effects of NASH therapeutics and the
unavailability of specialized diagnostic tests
for non-alcoholic fatty liver disease are
negatively impacting the growth of the NASH
biomarker market. North America holds the largest
market for the non-alcoholic steatohepatitis
(NASH) biomarker market, and is anticipated to
continue its stronghold till 2028. In the United
States, the market is primarily driven by the
rise in the prevalence of diabetes and obesity
among the population. Further, the expected
launch of pipeline molecules, along with the
early diagnosis of NASH, is another set of
factors motivating the NASH biomarker market's
growth. Above all, the favorable reimbursement
policies in the healthcare sector are also likely
to boost the studied market to a growth path
across North America. The key players established
in the NASH biomarker market are Siemens
Healthineers, Bristol Myers Squibb Company,
Allergan, Merck Co, Novo Nordisk, Zydus Cadila,
Gilead Sciences Inc, Novartis AG, AstraZeneca,
Genfit SA, Pfizer Inc, Viking Therapeutics, and
Madrigal Pharmaceuticals. The threat of new
players in the market is high as several
companies focus on conducting clinical trials.
Moreover, numerous small and medium players are
expected to enter the market by collaborating
with larger companies, increasing the threat of
new entrants. Furthermore, several new drugs for
the treatment of NASH are in the pipeline, with
multiple diagnostic tests likely to gain
approval. This is estimated to increase the level
of competition among existing market players in
the next few years.
Contact Us sales_at_tritonmarketresearch.com
Phone [phone]